CCDC104 Inhibitors

LY294002 and Wortmannin, by inhibiting PI3K, can disrupt AKT signaling, a pathway that may intersect with CCDC104's functionality in regulating cell growth and survival. Similarly, MEK inhibitors like PD98059 and U0126 can impact the ERK pathway, a critical mediator of cell cycle and division, where CCDC104 may play a role. The inhibition of stress-activated JNK by SP600125 or p38 MAP kinase by SB203580 could also modulate the function of CCDC104 if it is involved in cellular stress responses. Aurora kinase inhibitors like ZM-447439 are known to influence cell cycle-related proteins, which may include CCDC104 if it participates in mitotic processes.

In the context of protein turnover, Bortezomib can affect CCDC104's stability by inhibiting the proteasome, the main machinery responsible for protein degradation. Trichostatin A alters gene expression patterns by inhibiting histone deacetylases, affecting CCDC104 if its expression is chromatin-dependent. Cyclosporin A's inhibition of calcineurin might affect proteins involved in immune response pathways, which could impinge on CCDC104's role in such pathways. Staurosporine's wide-ranging inhibition of kinases may affect the phosphorylation state and, consequently, the activity of CCDC104.